A new India-Uzbekistan strategic partnership puts pharmaceutical manufacturing, localization and technology transfer at the centre of the next phase of cooperation.
Uzbekistan’s pharmaceutical story is no longer simply about supplying a growing domestic market.
It is about building the manufacturing capability behind it.
And the latest developments with India make that opportunity particularly relevant for pharmaceutical technology companies.
During Prime Minister Narendra Modi’s state visit to Uzbekistan on 29–30 August 2026, India and Uzbekistan elevated their relationship to a Comprehensive Strategic Partnership. Among the areas highlighted in the joint statement was pharmaceutical cooperation, with both countries recognizing the potential of the Tashkent Pharma Park Innovative Scientific and Industrial Pharmaceutical Cluster to facilitate joint projects, investment in modern pharmaceutical manufacturing, localization, technology transfer and workforce development.
The two sides also expressed support for establishing joint pharmaceutical manufacturing enterprises in Uzbekistan in cooperation with Indian companies.
That is a significant signal.
For Indian pharmaceutical machinery manufacturers, cleanroom specialists, packaging technology companies, engineering firms, laboratory technology providers and turnkey project contractors, Uzbekistan’s opportunity is moving from being a broad market prospect to something more concrete:
India and Uzbekistan are actively discussing the manufacturing partnerships that can create the next generation of pharmaceutical capacity.
From Import Dependence to Local Manufacturing
Uzbekistan has already made significant progress in developing its pharmaceutical industry.
Over the past nine years, more than US$1.8 billion has been invested in the sector, resulting in the launch of 140 new production facilities. More than 300 pharmaceutical enterprises now operate in the country, while locally manufactured pharmaceutical products are exported to 55 countries.
Yet the country’s ambitions extend considerably further.
Uzbekistan is seeking to increase domestic production, reduce import dependence, attract international investment and develop manufacturing capabilities that can serve both its domestic market and the wider region.
In 2026, the government announced targets including US$1 billion in pharmaceutical investment, increasing the share of domestically produced medicines in the market to 70% by 2030, and taking pharmaceutical exports to US$1 billion within five years.
This changes the nature of the opportunity.
Uzbekistan does not simply need more pharmaceutical products.
It needs the factories, technologies, infrastructure and expertise required to manufacture them locally.
India’s Role Is Becoming More Strategic
The relationship between India and Uzbekistan in pharmaceuticals is not new.
The two countries have been cooperating in pharmaceuticals, healthcare and capacity building for years. But recent developments indicate a shift towards deeper industrial collaboration.
In June 2026, Uzbekistan’s pharmaceutical authorities met the management of Dr. Reddy’s Laboratories to discuss the country’s pharmaceutical reforms, manufacturing infrastructure, localization and the development of the BioPharma City pharmaceutical cluster.
In August, discussions with Mankind Pharma covered investment projects in Uzbekistan, modern medicine production, R&D, technology transfer and high-technology manufacturing with higher added value.
And during the India-Uzbekistan Business Forum earlier in August, India’s Commerce and Industry Minister Piyush Goyal called on businesses from both countries to co-invest, co-manufacture and co-innovate, while highlighting opportunities in healthcare and advanced manufacturing.
Taken together, these developments point to a broader shift.
The India-Uzbekistan pharmaceutical relationship is moving beyond trade towards manufacturing collaboration.
For technology suppliers, that distinction is important.
The Factory Opportunity Is Expanding
New pharmaceutical manufacturing capacity creates demand across an entire ecosystem.
As Uzbekistan develops local production, opportunities can emerge across:
- Pharmaceutical processing machinery
- Tablet and capsule manufacturing
- Injectable and sterile manufacturing
- API manufacturing equipment
- Packaging and filling systems
- Cleanrooms and HVAC
- Water purification and utility systems
- Laboratory and analytical technologies
- Inspection and quality-control systems
- Automation and digital manufacturing
- Engineering and validation
- Turnkey manufacturing projects
A new injectable facility, for example, requires far more than a filling line. It needs cleanroom infrastructure, HVAC, purified water, sterilization, inspection, packaging, laboratory systems and validation.
Similarly, a new formulation plant can require processing, granulation, compression, coating, packaging and automation technologies.
This is why Uzbekistan’s pharmaceutical push can create opportunities for companies across the manufacturing value chain.
The opportunity is not one machine. It is the manufacturing ecosystem around it.
Technology Transfer Is Becoming a Key Part of the Opportunity
One of the clearest signals from Uzbekistan is its emphasis on technology transfer.
In June 2026, Deputy Minister of Investment, Industry and Trade Shokhrukh Gulamov said Uzbekistan could offer stronger incentives to Indian pharmaceutical companies, including tax incentives and subsidies for technology transfer, industrial-cluster participation and export-oriented production. He also highlighted joint ventures with local partners as a potential route to expanding production capacity.
This is significant because it broadens the opportunity for Indian companies.
The commercial model does not have to be limited to exporting equipment.
It can include:
Technology partnerships.
Local manufacturing.
Joint ventures.
Turnkey projects.
Licensing and technology transfer.
Technical services and validation.
Long-term equipment and lifecycle support.
For companies that can combine technology with engineering and manufacturing expertise, the opportunity can therefore extend well beyond a conventional equipment sale.
Uzbekistan Is Building for Regional Reach
There is also a regional dimension to the country’s strategy.
Uzbekistan is Central Asia’s largest consumer market, with a population of more than 38 million, and CaPhEx positions the country as a gateway to a wider Central Asian market covering Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan. The exhibition estimates the broader regional market at more than US$120 billion.
For pharmaceutical manufacturers and technology companies, this creates an additional strategic consideration.
A manufacturing investment in Uzbekistan can potentially be designed not only to serve local demand, but also to support regional distribution and exports.
That makes localization more commercially meaningful.
Why Indian Technology Companies Should Pay Attention
India brings a particularly relevant combination of pharmaceutical manufacturing experience, engineering capability and cost competitiveness.
Indian companies operate across many of the technology categories Uzbekistan needs as it develops its manufacturing base—from processing and packaging to cleanrooms, HVAC, water systems, laboratory equipment, automation and turnkey engineering.
More importantly, Indian pharmaceutical companies are already being actively engaged by Uzbekistan’s pharmaceutical authorities.
That gives Indian technology suppliers a timely reason to look beyond the traditional export model.
The question is no longer simply:
“Can we sell our equipment in Uzbekistan?”
It is:
“Can we become part of the manufacturing projects Uzbekistan and India are now seeking to build together?”
The Opportunity Starts Before Procurement
Pharmaceutical manufacturing projects rarely begin with a purchase order.
They begin with an investment decision, followed by feasibility studies, facility planning, process design, technology evaluation and technical discussions.
By the time a formal enquiry reaches procurement, many of the important technical decisions may already have been influenced.
For international technology companies, early market engagement therefore matters.
Understanding where projects are being planned, identifying local manufacturers and investors, finding the right partners and establishing technical relationships before procurement begins can create a significant advantage.
In a market where the manufacturing ecosystem is still developing, entering early can be particularly valuable.
CaPhEx 2026: Where the Opportunity Comes Together
The timing makes Central Asia Pharma Expo (CaPhEx) 2026 particularly relevant.
Taking place on 27–28 October 2026 at Anhor Park Exhibition Area in Tashkent, CaPhEx is positioned as a gateway to Central Asia’s pharmaceutical industry and is organized with the support of the Pharmaceutical Industry Development Agency, Ministry of Health, Republic of Uzbekistan.
The exhibition covers pharmaceutical processing and packaging machinery, API manufacturing, cleanroom and utility systems, water treatment, project consultancy, turnkey contracting and other technologies across the pharmaceutical manufacturing value chain. Its visitor profile includes manufacturers, plant and engineering teams, QA/QC and R&D professionals, procurement teams, regulators, investors, distributors and other industry stakeholders.
For companies evaluating Uzbekistan and the wider Central Asian region, CaPhEx offers an opportunity to meet the people shaping this manufacturing build-out while the market is still evolving.
Uzbekistan is moving from importing more medicines to manufacturing more of them.
And with India and Uzbekistan now explicitly supporting joint pharmaceutical manufacturing, localization and technology transfer, the next phase of that journey could create opportunities far beyond finished pharmaceuticals.
The manufacturing base is being built. The next question is who will supply the technology behind it.
Sources
- Government of India, Press Information Bureau — Joint Statement during the State Visit of Prime Minister Narendra Modi to Uzbekistan, 30 August 2026.
- Government of India, Press Information Bureau — India-Uzbekistan Business Forum, 3 August 2026.
- Pharmaceutical Industry Development Agency of Uzbekistan — Meeting with Dr. Reddy’s Laboratories, 5 June 2026.
- Pharmaceutical Industry Development Agency of Uzbekistan — Cooperation prospects with Mankind Pharma, 5 August 2026.
- Economic Times Pharma — Uzbekistan can provide more incentives to Indian pharma firms, aims to become regional hub for supply, 7 June 2026.
CaPhEx 2026 — Official exhibition website and exhibitor information.
